chevron_leftBack
As of 14 June 2026, Anebulo Pharmaceuticals, Inc. has a market cap of $19.71M USD, ranking #37178 globally and #5004 in the United States.
It ranks #3335 in the Healthcare sector, and #1113 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$19.71MUSD
Enterprise Value
$10.67MUSD
Net Income (TTM)
-$7.98MUSD
PB Ratio
2.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Richard Cunningham
open_in_new
Employees
3
Founded
2020
Website
anebulo.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0% | -17% | -52% | -50% | -84% | -63% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ANEB
Anebulo Pharmaceuticals Inc
ISIN: US0345691036
Shares Out.:
Shares Outstanding:
40.785M1
Shares Float:
24.13M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.4830 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company’s lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
4M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
3M%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
2M%
|
97.4
|
|
NYSE: MRK
|
$274.03B
1M%
|
15.1
|
|
NYSE: PFE
|
$149.38B
758K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
597K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
2M%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
1M%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
1M%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
923K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
559K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
550K%
80.96B GBP
|
14.6
|
chevron_leftBack